Among people with cystic fibrosis (CF), antibiotic-resistant Staphylococcus aureus is sometimes transmitted among relatives, but rarely in healthcare settings, an…
Articles by Marisa Wexler, MS
A novel compound that may hold promise for treating the roughly 11% of cases of cystic fibrosis (CF) that…
Eloxx Pharmaceuticals announced it expects to share data later this year from the first four treatment groups of a Phase…
Health Canada has approved Trikafta as a triple-combination therapy for people with cystic fibrosis (CF), ages 12 and…
A new strategy to correct so-called splicing mutations could help deliver nucleic acid therapies called oligonucleotides to cells in the…
A collaboration between the Cystic Fibrosis Foundation and Deep Science Ventures aims to identify technologies that might overcome the challenges…
BX004, a phage therapy candidate for Pseudomonas aeruginosa infections in people with cystic fibrosis (CF), was able to effectively kill a range…
The first participants have been dosed in the first clinical trial testing EDT001, an investigational therapy for cystic fibrosis…
The U.S. Food and Drug Administration (FDA) has approved expanding the use of Trikafta (elexacaftor, tezacaftor, and ivacaftor) to…
A combination of bacteria-infecting viruses and antibiotics can be used to effectively protect lung cells against infection by Pseudomonas…